Biomea Fusion Announces Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022
Biomea Fusion announced the acceptance of its abstract for presentation at the upcoming American Diabetes Association Scientific Sessions, scheduled for June 3-7, 2022. The presentation will focus on preclinical data for BMF-219, a novel treatment for type 2 diabetes. The company plans to initiate a Phase I/II clinical trial of BMF-219 in the second half of 2022, pending IND application clearance. Biomea aims to develop irreversible small molecules to treat genetically defined cancers and metabolic diseases, and sees significant potential in BMF-219 as an oral treatment for diabetes.
- Abstract accepted for presentation at the ADA Scientific Sessions, enhancing visibility.
- Planned Phase I/II clinical trial of BMF-219 indicates progress in development.
- BMF-219 aims to provide a novel, orally administered treatment for type 2 diabetes.
- Clinical trial initiation is contingent on IND submission and clearance, introducing uncertainty.
- -
- Biomea to present preclinical data from multiple in vivo studies
- Biomea plans to initiate a Phase I/II clinical trial of BMF-219 in diabetes in the second half of 2022, subject to submission and clearance of an investigational new drug (IND) application
REDWOOD CITY, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that an abstract has been accepted at the upcoming American Diabetes Association (ADA) 82nd Scientific Sessions. The ADA 82nd Scientific Sessions will be held from June 3-7, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.
“We are very excited that our abstract highlighting preclinical in vivo data has been accepted for presentation at this year’s American Diabetes Association Scientific Sessions. This is a significant milestone for our company as we work to advance BMF-219 toward the clinic later this year as a treatment for type 2 diabetes, marking the second therapeutic area we will evaluate with this product candidate in addition to multiple cancer types. Based on its unique profile, we believe BMF-219 has the potential to deliver a truly novel, orally administered treatment with a durable effect for type 2 diabetes,” said Thomas Butler, Biomea’s CEO and Chairman of the Board.
Biomea will disclose additional information about the presentation in alignment with the American Diabetes Association’s abstract embargo policies.
About Menin in Diabetes
Loss of functional beta-cell mass is a core component of the natural history in both types of diabetes — type 1 diabetes (mediated by autoimmune dysfunction) and type 2 diabetes (mediated by metabolic dysfunction). Beta-cells are found in the pancreas and are responsible for the synthesis and secretion of insulin. Insulin is a hormone that helps the body use glucose for energy and helps control blood glucose levels. In patients with diabetes, beta-cell mass and function are diminished, leading to insufficient insulin secretion and hyperglycemia. Menin is thought to act as a brake on beta-cell turnover / beta-cell growth, supporting the notion that inhibition of menin could lead to the regeneration of normal healthy beta-cells. Based on these and other scientific findings, Biomea explored the potential for menin inhibition as a viable therapeutic approach to permanently halt or reverse progression of type 2 diabetes.
About Biomea Fusion
Biomea Fusion is a biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. An irreversible small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional reversible drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. The company is utilizing its proprietary FUSION™ System to advance a pipeline of irreversible-binding therapeutic agents against key oncogenic drivers of cancer and metabolic diseases. Biomea Fusion’s goal is to utilize its capabilities and platform to become a leader in developing irreversible small molecules in order to maximize the clinical benefit when treating various cancers and metabolic diseases.
Forward-Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development programs, including BMF-219, the potential of BMF-219 as a treatment for various types of cancer and diabetes, our research, development and regulatory plans, including our plans to initiate a Phase I/II clinical trial of BMF-219 in type 2 diabetes subject to the submission and clearance of an IND, and the timing of such events, may be deemed to be forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions.
Any forward-looking statements in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including the risk that we may encounter delays in patient enrollment and in the initiation, conduct and completion of our planned clinical trials and other research and development activities. These risks concerning Biomea Fusion’s business and operations are described in additional detail in its periodic filings with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent periodic report filed with the SEC and subsequent filings thereafter. Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact:
Van Sandwick
Director, Investor Relations & Corporate Development
vsandwick@biomeafusion.com
(650) 460-7759
FAQ
What is Biomea Fusion's plan for BMF-219 in 2022?
When will Biomea Fusion present its preclinical data?
What does BMF-219 aim to treat?
What is the significance of the ADA Scientific Sessions for Biomea Fusion?
What are the potential benefits of BMF-219?
